Company: ABBV
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001551152-25-000040
Chunk: 10

Company: AbbVie Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 2
Chunk 10
---
(9.3)%(7.3)%Other Key ProductsMavyretUnited States$184 $167 9.7 %9.7 %$326 $311 4.9 %4.9 %International191 202 (5.1)%(6.5)%355 407 (12.8)%(11.2)%Total$375 $369 1.6 %0.8 %$681 $718 (5.1)%(4.2)%CreonUnited States$404 $372 8.4 %8.4 %$759 $657 15.4 %15.4 %Linzess/ConstellaUnited States$247 $211 17.4 %17.4 %$386 $468 (17.4)%(17.4)%International11 10 10.8 %10.3 %20 19 7.0 %9.7 %Total$258 $221 17.1 %17.1 %$406 $487 (16.5)%(16.4)%All other$603 $810 (25.4)%(24.8)%$1,350 $1,554 (13.1)%(12.5)%Total net revenues$15,423 $14,462 6.6 %6.5 %$28,766 $26,772 7.4 %8.0 %

n/m – Not meaningful

The following discussion and analysis of AbbVie’s net revenues by product is presented on a constant currency basis.

Net revenues for Skyrizi increased 62% for the three months and 66% for the six months ended June 30, 2025 primarily driven by continued strong market share uptake as well as market growth across all indications.

Net revenues for Rinvoq increased 41% for the three months and 49% for the six months ended June 30, 2025 primarily driven by continued strong market share uptake as well as market growth across all indications.

Net revenues for Humira decreased 58% for the three months and 54% for the six months ended June 30, 2025 primarily driven by continued impact of direct biosimilar competition following the loss of exclusivity. 

Net revenues for Vraylar increased 16% for the